Use access key #2 to skip to page content.

Vet67to82 (< 20)

BioTechnology HOMERUN potentials



May 01, 2010 – Comments (6) | RELATED TICKERS: CUR , DNDNQ

  I 'd bought and sold  Dendreon Corp (NASDAQ:DNDN) several times in my IRA's.  The first time I recommended DNDN here was 02/05/2009 and my start price was $3.56 ... yep, $3.56.  I rec'd DNDN because I was certain a positive outcome was close.  I closed my real world and MFool DNDN picks on 4/13/2009 @ $7.34 for a nice gain in a little over 2 months, vs the S&P's SPY,  of 104.30 %.   The next day ... the positive outcome I was expecting sent DNDN through the roof ... DNDN opened at $21.40 ... hit a intraday high of $22.1 ... and closed at $16.99. 

  Smiling, ... I'm not complaining.  I LOCKED in a gain.  Yep, I missed out on the further runs to the upside in DNDN  ... but I haven't been sitting on my hands.  My new 100 star BioTechnology pick with HOMERUN potential is  Neuralstem Inc. (CUR).   Neuralstem has studies going on in Germany and the USA for different afflictions.  Neuralstem has recently come to the attention of the press due a report (favorable) by the University Hospital at a conference in France.  

 Check out the recent article: "  Neuralstem's ALS Stem Cell Treatment Featured on CNN "
April 30, 2010 11:18 AM ET   ROCKVILLE, Md., April 30 /PRNewswire-FirstCall/ --

For the rest of the story:


 and a video news report: " CNN's Dr. Sanjay Gupta reports on a new stem cell clinical trial that is making history. "   For the video ....

(2) (

   and under Health:   " Stem cell Medical Breakthrough?"

 also, check out the Motley Fool CUR quote and comment  page.   There's only seven of us now. 


6 Comments – Post Your Own

#1) On May 01, 2010 at 9:42 PM, ragedmaximus (< 20) wrote:

thanks I'll check out cur i bought half my dndn at 42 and the other at 52 and was wondering your longterm stock price on dndn and why dont you get some here,has dndn finished it's run i think it could get to be a high dollar stock in the next 5 years what you think vet67?  also i think the fastest ways to outsized riches are in biotech stocks ,nothing flys like these except jets.also alot of volitility in biostocks but since the majority trade really low theres not much downside until they pop and then they can go back 

Report this comment
#2) On May 02, 2010 at 1:51 AM, Vet67to82 (< 20) wrote:

Thanks for your reply ragedmaximus.  

  I agree with you ... I don't think DNDN has finished its run.   There may be MUCH, much more to the treatment of different cancers with Dendreon's biotechnology ... so this may very well just be the tip of the iceberg.  

 If the FDA authorizes new studies for additional different cancer afflictions ... then I'll buy more DNDN.  The FDA is not going to authorize new studies .. unless  Dendreon submits a request ... and the request will tell us what cancer type(s) DNDN is looking at, the potential number of patients (target market), and we can then calculate the potential positives to DNDN's bottom line,    

Report this comment
#3) On May 03, 2010 at 6:57 PM, Vet67to82 (< 20) wrote:

Hot off the presses ....

UM researcher to test stem cell treatment for Alzheimer's

Results from ALS trials spur optimism
By Ryan Beene And Tom Henderson

Buoyed by early results of stem cell-based trials on patients with Lou Gehrig's disease, Eva Feldman, M.D., co-director of the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School, is now taking aim at a far bigger target: Alzheimer's disease.

In late April, Feldman began raising $1.5 million from private donors to fund animal trials for a stem cell-based treatment of Alzheimer's, a progressive degenerative disease that severely impacts brain function and afflicts more than 5.3 million people in the U.S. It is the seventh-leading cause of death in the nation.

.... for the rest of the story:

Report this comment
#4) On May 03, 2010 at 7:00 PM, Vet67to82 (< 20) wrote:

**** This was the hospital that reported favorable Neuralstem results in its trial ...: 

 "Neuralstem Enters Collaborative Stem Cell Agreement For Huntington's Disease in Germany"

ROCKVILLE, Md., Nov. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that it has entered into a collaboration with Professor Guido Nikkah Ph.D, of Albert-Ludwigs-University in Freiburg, Germany, to advance development of Neuralstem's human neural stem cell therapies. The collaboration with Professor Nikkah will focus on Huntington's disease...

... Read the full article on

Report this comment
#5) On May 03, 2010 at 7:02 PM, Vet67to82 (< 20) wrote:

AND check out the list of Patents ... in multiple countries AND the list of Patents Pending ... 


Report this comment
#6) On May 10, 2010 at 1:43 PM, Bad2dBone99 (< 20) wrote:

+1 rec

Report this comment

Featured Broker Partners